Catalyst
Slingshot members are tracking this event:
Aimmune (AIMT) to Complete Up-dosing of Peanut Allergy Patients Taking AR101 in Phase 3 PALISADE Trial in H1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AIMT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 06, 2017
Occurred Source:
http://ir.aimmune.com/phoenix.zhtml?c=254097&p=irol-pressReleasesArticle&ID=2251731
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Up-dosing, Peanut Allergies, Ar101, Phase 3 Palisade Trial
